纺锤体检查点功能复合物基因MAD1L1遗传变异与潮汕地区女性乳腺癌易感性研究

doi:10.3969/j.issn.1004-616x.2018.03.009

Abstract

Abstract: OBJECTIVE: To investigate associations between genotypic polymorphisms of the mitotic checkpoint gene,MAD1L1,and risk of breast cancer among women in the Chaoshan area. METHODS: This was a case-control study consisted of 191 new cases of breast cancer selected from the Tumor Hospital of SUMC between December,2015 and December,2017 and 225 healthy resident controls at the same period. TaqMan allelic discrimination was used to genotype the MAD1L1 locus rs1801368,and related information such as demographic characteristics,reproductive factors,smoking and drinking status,medical history and clinicopathological indexes for the cases were collected. RESULTS: The CC,CT and TT genotypes of rs1801368 accounted for 20.63%,42.86%,36.51% in the cases,and accounted for 30.14%,41.15%,28.71% in controls,genotype distribution showed no statistical significance between cases and controls,while logistic regression analysis showed that after adjusting the confounding factors such as age,age of menarche,menopause and so on,women carrying mutant homozygous TT genotype were more susceptible to breast cancer than those with wild homozygous CC genotype (OR=3.399,95% CI:1.288-8.973,P=0.013). CONCLUSION: Genetic variation of the SNP locus rs1801368 in mitotic checkpoint gene MAD1L1 was associated with breast cancer risk. Therefore,women who had the variant genotype would be susceptible to breast cancer.

Key words: breast cancer, spindle assembly checkpoint, MAD1L1, genetic susceptibility

CLC Number:

R737.9

YANG Shaoyi, ZHANG Qingying, WU Jundong, LIN Qiuqiang, WANG Ruifeng, ZHENG Qingyuan, CAI Fen. Genetic variations in the mitotic checkpoint gene MAD1L1, and risk for breast cancer[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(3): 209-213.

References

[1] TORRE L A,BRAY F,SIEGEL R L,et al. Global cancer statistics,2012[J]. CA Cancer J Clin,2015,65(2):87-108.
[2] FAN L,STRASSER-WEIPPL K,LI J J,et al. Breast cancer in China[J]. Lancet Oncol,2014,15(7):279-289.
[3] LI T,MELLO-THOMS C,BRENNAN P C. Descriptive epidemiology of breast cancer in China:incidence,mortality,survival and prevalence[J]. Breast Cancer Res Treat,2016,159(3):395-406.
[4] LO Y L,YU J C,CHEN S T,et al. Breast cancer risk associated with genotypic polymorphism of the mitotic checkpoint genes:a multigenic study on cancer susceptibility[J]. Carcinogenesis,2007,28(5):1079-1086.
[5] KOPS G J,WEAVER B A,CLEVELAND D W. On the road to cancer:aneuploidy and the mitotic checkpoint[J]. Nat Rev Cancer,2005,5(10):773-785.
[6] ZHONG R,CHEN X,CHEN X,et al. MAD1L1 Arg558His and MAD2L1 Leu84Met interaction with smoking increase the risk of colorectal cancer[J]. Sci Rep,2015,5:12202.
[7] NASMYTH K. How do so few control so many?[J]. Cell,2005,120(6):739-746.
[8] MAPELLI M,MASSIMILIANO L,SANTAGUIDA S,et al. The Mad2 conformational dimer:structure and implications for the spindle assembly checkpoint[J]. Cell,2007,131(4):730-743.
[9] HEINRICH S,SEWART K,WINDECKER H,et al. Mad1 contribution to spindle assembly checkpoint signalling goes beyond presenting Mad2 at kinetochores[J]. Embo Reports,2014,15(3):291.
[10] GUO Y,ZHANG X,YANG M,et al. Functional evaluation of missense variations in the human MAD1L1 and MAD2L1 genes and their impact on susceptibility to lung cancer[J]. J Med Genet,2010,47(9):616-622.
[11] BHARADWAJ R,YU H. The spindle checkpoint,aneuploidy,and cancer[J]. Oncogene,2004,23(11):2016-2027.
[12] YUAN B,XU Y,WOO J H,et al. Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability[J]. Clin Cancer Res,2006,12(2):405-410.
[13] SUN Q,ZHANG X,LIU T,et al. Increased expression of mitotic arrest deficient-like 1(MAD1L1) is associated with poor prognosis and insensitive to Taxol treatment in breast cancer[J]. Breast Cancer Res Treat,2013,140(2):323-330.
[14] PUJANA M A,HAN J D,STARITA L M,et al. Network modeling links breast cancer susceptibility and centrosome dysfunction[J]. Nat Genet,2007,39(11):1338-1349.
[15] 曹莉,姚广裕,胡晓磊,等. 代谢综合征与乳腺癌关系的研究进展[J]. 中华外科杂志,2015,53(12):966-969.
[16] CAPASSO I,ESPOSITO E,PENTIMALLI F,et al. Metabolic syndrome affects breast cancer risk in postmenopausal women:National Cancer Institute of Naples experience[J]. Cancer Biol Ther,2014,10(12):1240-1243.
[17] 陶苹,胡耀月,黄源,等. 亚裔女性乳腺癌危险因素的Meta分析[J]. 中华流行病学杂志,2011,32(2):164-169.
[18] GEZGEN G,ROACH E C,KIZILARSLANOGLU M C,et al. Metabolic syndrome and breast cancer:an overview[J]. J Buon,2012,17(2):223.

Genetic variations in the mitotic checkpoint gene MAD1L1, and risk for breast cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	XIN Yumeng, LIANG Huanxi, YU Yuehua, SUN Zhenxiao. Network pharmacology and molecular docking mechanisms of licorice and dried ginger decoction against breast cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 7-13.
[2]	ZHAO Yan, SUN Zhenxiao. Metformin inhibitd proliferation and migration of human breast cancer cell in vitro [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 35-39.
[3]	FANG Yutong, ZHANG Qunchen, HONG Chaoqun, CHEN Chunfa, CHEN Jiongyu, ZHANG Rendong, WU Jundong. Mechanisms of miR-221 and miR-222 on expression of GATA3 and FOXA1 and their effects in breast cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 435-441,460.
[4]	ZHANG Shimin, ZHAO Ruijun. Expression of protein tyrosine phosphatase receptor J in breast cancer tissues and its relationship with clinical prognosis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 276-279,285.
[5]	CHENG Bin, WANG Xinyu, SUN Yu, ZHANG Jiatai, DONG Shuying. Inhibition of metformin on phthalate-induced proliferation and migration of MCF-7 breast cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 197-202.
[6]	LUO Jiao, ZHANG Kunchi, ZHOU Li. Analysis of differentially expressed microRNAs between the triple negative breast cancer cell line MDA-MB-231 and its brain metastasis cell line [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 218-224.
[7]	LI Weiwei, ZHU Ying. Data mining analyses of expression and prognostic values of the MYB family in breast cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 414-422.
[8]	CHEN Mianling, MA Shuoyi. Regulation of migration and invasion of triple-negative breast cancer cell MDA-MB-231 by miR-21 via targeting PDCD4 [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(4): 292-297.
[9]	ZHANG Huijuan, HUANG Dayuan, ZHANG Jie, TANG Haiou, XIE Anxin, TAN Dunyong. Effects of SF1a-PRLR and ΔS2 SF1a-PRLR on proliferation and microRNA expressionin MCF-7 breast cancer cell [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(3): 203-208.
[10]	SUN Quanwu, DU Xiaoping, HAO Jie, SHI Rong, LIU Bo, HUANG Haiyun. β1 integrin expression in breast cancer patients with pathological nipple discharge [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(5): 368-372.
[11]	WANG Lan, ZHANG Yongdong, GUO Hongyun, WANG Tao, WANG Haitao, GUO Huan, YANG Suisheng, LI Xiaoqin, SU Haixiang. Relationships between XRCC3 polymorphisms and breast cancer in northern Chinese women [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(5): 392-396,400.
[12]	YING Wei, WANG Xingyuan, JIANG Bo, ZHOU Wei. Association between polymorphisms in the miR-146a and susceptibility to non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(3): 222-226.
[13]	DU Juan, HU Xiangyang, LIU Dan, HU Wei, CHEN Tao. Inhibitory effect of total alkaloids of Tougucao on bone metastasis of breast cancer cells in mice [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(6): 435-441.
[14]	XIAO Hongmei, PAN Tianqi, DONG Shunan, FU Lingmeng, WANG Shaokang, SUN Guiju. Menopausal status on risk for breast cancer from tea consumption: a meta-analysis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(5): 395-399.
[15]	JIANG Pengtao, HU Zhifang, GAO Xingchun, GUO Na, ZHANG Dian, JIANG Fengliang. Involvement of p53 in regulation of DNA damage-induced cell death in MDA-MB-231 [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(5): 349-353.